- Home
- ROMA vs PSTV Comparison
ROMA vs PSTV Comparison
Compare ROMA & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ROMA | PSTV |
|---|---|---|
| Founded | 2018 | 1996 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 144.7M | 61.1M |
| IPO Year | 2024 | N/A |
Fundamental Metrics
Financial Performance| Metric | ROMA | PSTV |
|---|---|---|
| Price | $2.39 | $0.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.25 |
| AVG Volume (30 Days) | 3.3K | ★ 6.2M |
| Earning Date | 12-26-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,568,345.00 | ★ $5,258,000.00 |
| Revenue This Year | N/A | $28.21 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 23.21 | N/A |
| 52 Week Low | $0.58 | $0.16 |
| 52 Week High | $4.66 | $2.31 |
Technical Indicators
Market Signals| Indicator | ROMA | PSTV |
|---|---|---|
| Relative Strength Index (RSI) | 41.24 | 42.20 |
| Support Level | $2.18 | $0.61 |
| Resistance Level | $2.68 | $0.65 |
| Average True Range (ATR) | 0.14 | 0.06 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 36.10 | 1.86 |
Price Performance
Historical ComparisonAbout ROMA Roma Green Finance Limited
Roma Green Finance Ltd is principally engaged in the provision of ESG, corporate governance and risk management as well as sustainability and climate change-related advisory services. The company works closely with its clients to help them understand, identify, manage, and overcome various business matters arising from such factors related to ESG, sustainability and climate change. Geographically, the company generates its revenue from Hong Kong and Singapore.
About PSTV PLUS THERAPEUTICS Inc.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).